IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-31557-0.html
   My bibliography  Save this article

Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome

Author

Listed:
  • Anahita Fathi

    (University Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD)
    Bernhard-Nocht-Institute for Tropical Medicine, Department for Clinical Immunology of Infectious Diseases
    German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems
    University Medical Center Hamburg-Eppendorf, First Department of Medicine, Division of Infectious Diseases)

  • Christine Dahlke

    (University Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD)
    Bernhard-Nocht-Institute for Tropical Medicine, Department for Clinical Immunology of Infectious Diseases
    German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems)

  • Verena Krähling

    (Philipps University Marburg, Institute of Virology
    German Center for Infection Research, partner site Gießen-Marburg-Langen)

  • Alexandra Kupke

    (Philipps University Marburg, Institute of Virology
    German Center for Infection Research, partner site Gießen-Marburg-Langen)

  • Nisreen M. A. Okba

    (Erasmus Medical Center, Department of Viroscience)

  • Matthijs P. Raadsen

    (Erasmus Medical Center, Department of Viroscience)

  • Jasmin Heidepriem

    (Max Planck Institute of Colloids and Interfaces, Department of Biomolecular Systems)

  • Marcel A. Müller

    (Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology
    German Center for Infection Research, partner site Berlin)

  • Grigori Paris

    (Max Planck Institute of Colloids and Interfaces, Department of Biomolecular Systems)

  • Susan Lassen

    (University Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD)
    Bernhard-Nocht-Institute for Tropical Medicine, Department for Clinical Immunology of Infectious Diseases
    German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems)

  • Michael Klüver

    (Philipps University Marburg, Institute of Virology
    German Center for Infection Research, partner site Gießen-Marburg-Langen)

  • Asisa Volz

    (University of Veterinary Medicine Hanover, Institute of Virology
    German Center for Infection Research, partner site Hanover-Brunswick)

  • Till Koch

    (Bernhard-Nocht-Institute for Tropical Medicine, Department for Clinical Immunology of Infectious Diseases
    German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems
    University Medical Center Hamburg-Eppendorf, First Department of Medicine, Division of Infectious Diseases)

  • My L. Ly

    (University Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD)
    Bernhard-Nocht-Institute for Tropical Medicine, Department for Clinical Immunology of Infectious Diseases
    German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems)

  • Monika Friedrich

    (University Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD)
    Bernhard-Nocht-Institute for Tropical Medicine, Department for Clinical Immunology of Infectious Diseases
    German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems)

  • Robert Fux

    (LMU University of Munich, Institute of Infectious Diseases and Zoonoses
    German Center for Infection Research, partner site Munich)

  • Alina Tscherne

    (LMU University of Munich, Institute of Infectious Diseases and Zoonoses
    German Center for Infection Research, partner site Munich)

  • Georgia Kalodimou

    (LMU University of Munich, Institute of Infectious Diseases and Zoonoses
    German Center for Infection Research, partner site Munich)

  • Stefan Schmiedel

    (German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems
    University Medical Center Hamburg-Eppendorf, First Department of Medicine, Division of Infectious Diseases)

  • Victor M. Corman

    (Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology
    German Center for Infection Research, partner site Berlin)

  • Thomas Hesterkamp

    (German Center for Infection Research, Translational Project Management Office)

  • Christian Drosten

    (Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology
    German Center for Infection Research, partner site Berlin)

  • Felix F. Loeffler

    (Max Planck Institute of Colloids and Interfaces, Department of Biomolecular Systems)

  • Bart L. Haagmans

    (Erasmus Medical Center, Department of Viroscience)

  • Gerd Sutter

    (LMU University of Munich, Institute of Infectious Diseases and Zoonoses
    German Center for Infection Research, partner site Munich)

  • Stephan Becker

    (Philipps University Marburg, Institute of Virology
    German Center for Infection Research, partner site Gießen-Marburg-Langen)

  • Marylyn M. Addo

    (University Medical Center Hamburg-Eppendorf, Institute for Infection Research and Vaccine Development (IIRVD)
    Bernhard-Nocht-Institute for Tropical Medicine, Department for Clinical Immunology of Infectious Diseases
    German Center for Infection Research, partner site Hamburg-Lübeck-Borstel-Riems)

Abstract

Vaccine development is essential for pandemic preparedness. We previously conducted a Phase 1 clinical trial of the vector vaccine candidate MVA-MERS-S against the Middle East respiratory syndrome coronavirus (MERS-CoV), expressing its full spike glycoprotein (MERS-CoV-S), as a homologous two-dose regimen (Days 0 and 28). Here, we evaluate the safety (primary objective) and immunogenicity (secondary and exploratory objectives: magnitude and characterization of vaccine-induced humoral responses) of a third vaccination with MVA-MERS-S in a subgroup of trial participants one year after primary immunization. MVA-MERS-S booster vaccination is safe and well-tolerated. Both binding and neutralizing anti-MERS-CoV antibody titers increase substantially in all participants and exceed maximum titers observed after primary immunization more than 10-fold. We identify four immunogenic IgG epitopes, located in the receptor-binding domain (RBD, n = 1) and the S2 subunit (n = 3) of MERS-CoV-S. The level of baseline anti-human coronavirus antibody titers does not impact the generation of anti-MERS-CoV antibody responses. Our data support the rationale of a booster vaccination with MVA-MERS-S and encourage further investigation in larger trials. Trial registration: Clinicaltrials.gov NCT03615911.

Suggested Citation

  • Anahita Fathi & Christine Dahlke & Verena Krähling & Alexandra Kupke & Nisreen M. A. Okba & Matthijs P. Raadsen & Jasmin Heidepriem & Marcel A. Müller & Grigori Paris & Susan Lassen & Michael Klüver &, 2022. "Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
  • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-31557-0
    DOI: 10.1038/s41467-022-31557-0
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-31557-0
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-022-31557-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Chek Meng Poh & Guillaume Carissimo & Bei Wang & Siti Naqiah Amrun & Cheryl Yi-Pin Lee & Rhonda Sin-Ling Chee & Siew-Wai Fong & Nicholas Kim-Wah Yeo & Wen-Hsin Lee & Anthony Torres-Ruesta & Yee-Sin Le, 2020. "Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients," Nature Communications, Nature, vol. 11(1), pages 1-7, December.
    2. Lingshu Wang & Wei Shi & M. Gordon Joyce & Kayvon Modjarrad & Yi Zhang & Kwanyee Leung & Christopher R. Lees & Tongqing Zhou & Hadi M. Yassine & Masaru Kanekiyo & Zhi-yong Yang & Xuejun Chen & Michell, 2015. "Evaluation of candidate vaccine approaches for MERS-CoV," Nature Communications, Nature, vol. 6(1), pages 1-11, November.
    3. Chunyan Wang & Rien Haperen & Javier Gutiérrez-Álvarez & Wentao Li & Nisreen M. A. Okba & Irina Albulescu & Ivy Widjaja & Brenda Dieren & Raul Fernandez-Delgado & Isabel Sola & Daniel L. Hurdiss & Ola, 2021. "A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies," Nature Communications, Nature, vol. 12(1), pages 1-15, December.
    4. Florian Krammer, 2020. "SARS-CoV-2 vaccines in development," Nature, Nature, vol. 586(7830), pages 516-527, October.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Timothy J. C. Tan & Zongjun Mou & Ruipeng Lei & Wenhao O. Ouyang & Meng Yuan & Ge Song & Raiees Andrabi & Ian A. Wilson & Collin Kieffer & Xinghong Dai & Kenneth A. Matreyek & Nicholas C. Wu, 2023. "High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    2. Tang, Lianhua & Li, Yantong & Bai, Danyu & Liu, Tao & Coelho, Leandro C., 2022. "Bi-objective optimization for a multi-period COVID-19 vaccination planning problem," Omega, Elsevier, vol. 110(C).
    3. Chan-I Su & Zih-Shiuan Chuang & Chi-Ting Shie & Hsin-I Wang & Yu-Ting Kao & Chia-Yi Yu, 2024. "A cis-acting ligase ribozyme generates circular RNA in vitro for ectopic protein functioning," Nature Communications, Nature, vol. 15(1), pages 1-10, December.
    4. X. Tong & R. P. McNamara & M. J. Avendaño & E. F. Serrano & T. García-Salum & C. Pardo-Roa & H. L. Bertera & T. M. Chicz & J. Levican & E. Poblete & E. Salinas & A. Muñoz & A. Riquelme & G. Alter & R., 2023. "Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    5. Laura Pérez-Alós & Cecilie Bo Hansen & Jose Juan Almagro Armenteros & Johannes Roth Madsen & Line Dam Heftdal & Rasmus Bo Hasselbalch & Mia Marie Pries-Heje & Rafael Bayarri-Olmos & Ida Jarlhelt & Seb, 2023. "Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    6. Ching-Lin Hsieh & Sarah R. Leist & Emily Happy Miller & Ling Zhou & John M. Powers & Alexandra L. Tse & Albert Wang & Ande West & Mark R. Zweigart & Jonathan C. Schisler & Rohit K. Jangra & Kartik Cha, 2024. "Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    7. Charles B. Stauft & Prabhuanand Selvaraj & Felice D’Agnillo & Clement A. Meseda & Shufeng Liu & Cyntia L. Pedro & Kotou Sangare & Christopher Z. Lien & Jerry P. Weir & Matthew F. Starost & Tony T. Wan, 2023. "Intranasal or airborne transmission-mediated delivery of an attenuated SARS-CoV-2 protects Syrian hamsters against new variants," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    8. Sun Jin Kim & Zhong Yao & Morgan C. Marsh & Debra M. Eckert & Michael S. Kay & Anna Lyakisheva & Maria Pasic & Aiyush Bansal & Chaim Birnboim & Prabhat Jha & Yannick Galipeau & Marc-André Langlois & J, 2022. "Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti-SARS-CoV-2 antibodies," Nature Communications, Nature, vol. 13(1), pages 1-9, December.
    9. Anneliese S. Ashhurst & Matt D. Johansen & Joshua W. C. Maxwell & Skye Stockdale & Caroline L. Ashley & Anupriya Aggarwal & Rezwan Siddiquee & Stefan Miemczyk & Duc H. Nguyen & Joel P. Mackay & Claudi, 2022. "Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    10. Phanramphoei N. Frantz & Aleksandr Barinov & Claude Ruffié & Chantal Combredet & Valérie Najburg & Guilherme Dias de Melo & Florence Larrous & Lauriane Kergoat & Samaporn Teeravechyan & Anan Jongkaeww, 2021. "A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters," Nature Communications, Nature, vol. 12(1), pages 1-17, December.
    11. Piñeiro-Chousa, Juan & López-Cabarcos, M. Ángeles & Quiñoá-Piñeiro, Lara & Pérez-Pico, Ada M., 2022. "US biopharmaceutical companies' stock market reaction to the COVID-19 pandemic. Understanding the concept of the ‘paradoxical spiral’ from a sustainability perspective," Technological Forecasting and Social Change, Elsevier, vol. 175(C).
    12. Laurent Renia & Yun Shan Goh & Angeline Rouers & Nina Bert & Wan Ni Chia & Jean-Marc Chavatte & Siew‐Wai Fong & Zi Wei Chang & Nicole Ziyi Zhuo & Matthew Zirui Tay & Yi-Hao Chan & Chee Wah Tan & Nicho, 2022. "Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    13. Caitlin I. Stoddard & Kevin Sung & Zak A. Yaffe & Haidyn Weight & Guillaume Beaudoin-Bussières & Jared Galloway & Soren Gantt & Judith Adhiambo & Emily R. Begnel & Ednah Ojee & Jennifer Slyker & Dalto, 2023. "Elevated binding and functional antibody responses to SARS-CoV-2 in infants versus mothers," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    14. Mark P. Khurana & Jacob Curran-Sebastian & Neil Scheidwasser & Christian Morgenstern & Morten Rasmussen & Jannik Fonager & Marc Stegger & Man-Hung Eric Tang & Jonas L. Juul & Leandro Andrés Escobar-He, 2024. "High-resolution epidemiological landscape from ~290,000 SARS-CoV-2 genomes from Denmark," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
    15. Andersson, Ola & Campos-Mercade, Pol & Meier, Armando N. & Wengström, Erik, 2021. "Anticipation of COVID-19 vaccines reduces willingness to socially distance," Journal of Health Economics, Elsevier, vol. 80(C).
    16. Alfredo Córdova-Martínez & Alberto Caballero-García & Enrique Roche & David C. Noriega, 2021. "β-Glucans Could Be Adjuvants for SARS-CoV-2 Virus Vaccines (COVID-19)," IJERPH, MDPI, vol. 18(23), pages 1-13, November.
    17. Yuexiu Zhang & Michelle Chamblee & Jiayu Xu & Panke Qu & Mohamed M. Shamseldin & Sung J. Yoo & Jack Misny & Ilada Thongpan & Mahesh KC & Jesse M. Hall & Yash A. Gupta & John P. Evans & Mijia Lu & Chen, 2024. "Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    18. Fulvio Lauretani & Marco Salvi & Irene Zucchini & Crescenzo Testa & Chiara Cattabiani & Arianna Arisi & Marcello Maggio, 2023. "Relationship between Vitamin D and Immunity in Older People with COVID-19," IJERPH, MDPI, vol. 20(8), pages 1-19, April.
    19. Chen, Ke & Li, Qiyuan & Shoaib, Muhammad & Ameer, Waqar & Jiang, Tao, 2024. "Does improved digital governance in government promote natural resource management? Quasi-natural experiments based on smart city pilots," Resources Policy, Elsevier, vol. 90(C).
    20. Carlos Ávila-Nieto & Júlia Vergara-Alert & Pep Amengual-Rigo & Erola Ainsua-Enrich & Marco Brustolin & María Luisa Rodríguez de la Concepción & Núria Pedreño-Lopez & Jordi Rodon & Victor Urrea & Edwar, 2024. "Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection," Nature Communications, Nature, vol. 15(1), pages 1-18, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-31557-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.